| DATE | APPLICATION NO. | | DATE | | |
|---|---|---|---|---|---|
| PI | JP 58092445 | A2 | 19830601 | JP 1981-189145 | 19811127 |
| | JP 63054412 | B4 | 19881027 | | |
| | | | | JP 1981-189145 | 19811127 |

L4 ANSWER 53 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Couplers (I; R1 = H, Clk, SO3H; R2 = H, Cl, OMe) possessing a combination of desirable properties and developing with agents of the p-phenylenediamine type brilliant, highly transparent dyes with absorption maximum at 645-690 nm are obtained by fusing Ph1-hydroxy-2-naphthoates with a nitroaniline, reducing the nitroamides to the amidoanilines, and condensing 2 moles of them with 1 mole of 5-octadecyloxy-isophthaloyl chloride. The color formers are used as aqueous alkaline solution or as solute dispersion.
AN 1973:117597 CAPLUS
DN 78:117597
TI Couplers for color photographic material
IN Mittag, Renate; Schindler, Wolfgang
PA VEB Filmfabrik Wolfen
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| PI DE 2153045 | A1 | 19730118 | DE 1971-2153045 | | 19711025 |
| | | | DD 1971-156304 | A2 | 19710706 |
| FR 2145143 | A5 | 19730216 | FR 1972-3293 | | 19720201 |
| | | | DD 1971-156304 | A | 19710706 |
| BE 780704 | A1 | 19720703 | BE 1972-115096 | | 19720315 |
| | | | DE 1971-2153045 | A | 19711025A |
| SU 433443 | T | 19740625 | SU 1972-1775191 | | 19720419 |
| | | | DD 1971-156304 | A1 | 19710706 |

L4 ANSWER 54 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Tuberculostatic and carcinostatic imidazolylbenzamides I (R = imidazolylaryl or imidazolylarylamino and the amide group is attached in the 3- or 4-position of the benzene ring) (94 compds.) were prepared Thus p-NCC6H4NHCOC6H4NH2-m was treated with p-NCC6H4NCO to give 3-(p-NCC6H4NHCO)C6H4NHCO-NHC6H4CN-p, treated with CS2 to give 3-(p-H2NCSC6H4NH-CO)C6H4NHCONHC6H4CSNH2-p, and cyclized with excess H2NCH2CH2NH2 to give II. II inhibited Mycobacterium tuberculosis at 6 mg/ml in vitro and increased the survival time of mice infected with leukemia CCNSC 1210 by 233.
AN 1972:564707 CAPLUS
DN 77:164707
TI Imidazolylbenzamides
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 22 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | CH 525896 | A | 19720731 | CH 1961-525896 | | 19610911 |
| | | | | CH 1969-12739 | A | 19610911 |

L4 ANSWER 55 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Tuberculostatic and carcinostatic imidazolylbenzamides I, (R = imidazolylaryl imidazolylarylamino and the amido group is substituted in the 2-, 3-, or 4-position on the benzene ring) (94 compds.) were prepared by cyclizing the benzoic esters with H2N-CH2CH2NH2. Thus 5.5 g II was obtained by treating 10 g p-(p-EtO2CC6H4NHCO)2C6H4 with 50 ml H2NCH2CH2NH2. II.2HCl had in vitro tuberculostatic activity at 5.5 mg/ml and at 25 mg/kg a day it prolonged the life of Leukemia CCNSC 1210-infected mice by 330.
AN 1972:564706 CAPLUS
DN 77:164706
TI Imidazolylbenzamides
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 22 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | CH 525897 | A | 19720731 | CH 1961-525897 | | 19610911 |
| | | | | CH 1969-12740 | A | 19610911 |

L4 ANSWER 56 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Tuberculostatic and carcinostatic imidazolylbenzamides I (R = imidazolylaryl or imidazolylarylamino and the amido group is substituted in the 3- or 4-position of the benzene ring) and some related pyrimidyl-benzamides (105 compds.) were prepared by cyclizing the benzo-imidoic esters with an alkylenediamine. Thus 11.5 g II-diacetate was obtained by treating 15 g p-(p-EtOC(:NH)C6H4NHCO)2C6-H4 with 30 ml H2NCH2CH2NH2. At 15 mg/kg a day II pro-longed the life of Leukemia CCNSC 1210-infected mice by 270.
AN 1972:564694 CAPLUS
DN 77:164694
TI Imidazolylbenzamides
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 25 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | CH 525898 | A | 19720731 | CH 1965-525898 | | 19650501 |
| | | | | CH 1970-4234 | A | 19650501 |

L4 ANSWER 57 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Bisamidino compds. (I), effective tuberculostatic and antileukemic agents

in mice, were prepared by reaction of an alkoxy analog of I (NR1R2 replaced by OR3, where R3 = alkyl) with R2R1NH. About 63 I (n = 0, 1; R = H, Me, Et, CHMe2; R1 = H, Me, Et; R2 = H, C1-4 alkyl, (CH2)3OMe; Z = NH, CH2, or single bond) were prepared

AN 1972:461630 CAPLUS
DN 77:61630
TI Highly basic compounds for chemotherapy
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 10 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI CH 520657 | A | 19720331 | CH 1961-520657 | 19610911 |
| | | | CH 1965-6015 A | 19610911 |

L4 ANSWER 58 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
AB Compds.; R1HNC(O)A(O)CNHR1 (I; R1 = alkyl, alkenyl, cycloalkyl, phenyl, phenylakyl, or phenylalkenyl; A = alkylene, phenylene, naphthylene, or biphenylene) are treated with COCl2 in the presence of amines and the reaction products treated further with R2NH2 (R2 = H or R1) to give the title compds., R2NH(R1N:)CAC(:NR1)NHR2 (II) useful as biocides. Thus, I [R1 = Et(CH2)5, A = CH2CH2SCH2CH2] in THF is mixed 30 min at 0° with dry pyridine and COCl2 in dry C6H6, the mixture kept 2 hr at 5-10°, mixed with petroleum ether, and n-hexylamine, kept 3 hr at room temperature and the product treated with saturated EtOH-(CO2H)2, to give 54% yield II.2(CO2H)2 [R1 = R2 = Me(CH2)5; A = CH2CH2SCH2CH2].
AN 1971:434674 CAPLUS
DN 75:34674
TI Substituted bisamidino compounds
IN Ookawa, Kanji; Abe, Jinnosuke; Taie, Teruo; Watanabe, Tetsuo; Fujimoto, Kentaro; Kuramoto, Masashi
PA Toyo Brewing Co., Ltd.
SO Jpn. Tokkyo Koho, 37 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI JP 46002803 | B4 | 19710123 | JP | 19670928 |

L4 ANSWER 59 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
AB A series of mono- and dianilido derivs. of 4-hydroxyisophthalic acid, such as 3-carbethoxy-4'-hydroxy-4-methoxybenzanilide, 5-carbomethoxy-2,4'-dihydroxybenzanilide, 3-carbethoxy-4,4'-dimethoxy-benzanilide, 5-carbomethoxy-2,4'-dimethoxybenzanilide, and 4-ethoxy-4',4''-dihydroxyisophthalanilide, were synthesized and screened for analgesic and antipyretic effects in mic e and rats, resp. The acute toxicity of 3-carbomethoxy-4,4'-dihydroxy-benzanilide, the most active compound in the series, was > 1000 mg/kg, i.p., in mice.
AN 1970:130810 CAPLUS
DN 72:130810
TI New mono- and dianilido derivatives of 4-hydroxy-isophthalic acid with

5/11/05

analgesic and antipyretic activity
AU Orzalesi, Gianni; Selleri, Renato; Caldini, Oreste; Fabrizi, P.
CS Soc. Italo-Brit. L. Manetti, H. Roberts Cie., Florence, Italy
SO Bollettino Chimico Farmaceutico (1969), 108(10), 619-31
CODEN: BCFAAI; ISSN: 0006-6648
DT Journal
LA French

L4 ANSWER 60 OF 69 CAP

10713566

L4 ANSWER 43 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI




I

AB Title compound I (R = 3-pyridylmethylamino, PhCH2NH, 4-MeC6H6NH, PhNMe, dibenzylamino, 4-O2NC6H4NH, cyclohexylamino, pyrrolidino, piperidino, morpholino, N-methylpiperazinyl, 2-pyridylamino, etc.) were prepared in 33.0-93.5% yield by amidation of I (R = OH) with amines.
AN 1992:571156 CAPLUS
DN 117:171156
TI Synthesis of a platelet antiaggregant-picotamide and its analogs
AU Tong, Zeen; Chen, Wenhao; Peng, Sixun
CS Div. Med. Chem., China Pharm. Univ., Nanjing, Peop. Rep. China
SO Zhongguo Yaoke Daxue Xuebao (1992), 23(1), 1-4
CODEN: ZHYXE9; ISSN: 1000-5048
DT Journal
LA Chinese

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN

AB Novel, non-peptidic small organic compds. having an affinity for cyclophilin (CyP)-type immunophilin proteins are reported. These compds. are used for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity. Thus, 5-HOC6H3(CO2Me)2-1,3 was O-benzylated, hydrolized to the acid and treated with 3,4-Cl2C6H3NH2 to give 5-PhCH2OC6H3(CONHC6H3Cl2-3,4)2-1,3. This compound gave complete protection against cell death in L-threo-3-hydroxyaspartic acid treated spinal cord slices.

AN 2002:575044 CAPLUS

DN 137:124993

TI Trisubstituted carbocyclic cyclophilin binding compounds and their use

IN Wu, Yong-Qian; Belyakov, Sergei; Hamilton, Gregory; Limburg, David; Steiner, Joseph; Vaal, Mark; Wei, Ling; Wilkinson, Douglas

PA Guilford Pharmaceuticals Inc., USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2002059080 | A2 | 20020801 | WO 2002-US2538 | | 20020125 |
| | WO 2002059080 | A3 | 20021219 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | CA 2435829 | AA | 20020801 | CA 2002-2435829 | | 20020125 |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | | | | WO 2002-US2538 | W | 20020125 |
| | US 2002165275 | A1 | 20021107 | US 2002-57203 | | 20020125 |
| | US 6656971 | B2 | 20031202 | | | |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291365P | P | 20010517 |
| | EP 1360173 | A2 | 20031112 | EP 2002-706049 | | 20020125 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | | | | WO 2002-US2538 | W | 20020125 |
| | JP 2004532187 | T2 | 20041021 | JP 2002-559382 | | 20020125 |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | | | | WO 2002-US2538 | W | 20020125 |
| | US 2004157919 | A1 | 20040812 | US 2003-713566 | | 20031114 |
| | | | | US 2002-57203 | A3 | 20020125 |

OS MARPAT 137:124993

L4 ANSWER 8 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN

AB A series of arylsulfonamide and arylamide derivs. have been prepared from anisole in good yields. The structures of those compds. were confirmed by 1H-NMR and MS anal. Their activities against platelet aggregation were tested in vitro by using the Born test on rabbits.

AN 2003:561679 CAPLUS
DN 139:395672

TI Design and synthesis of new arylsulfonamide and arylamide derivatives for the platelet aggression inhibitor

AU Wang, Song Qing; Liu, Xiu Jie; Yi, Zhi Ming; Zhao, Kang
CS The College of Pharmaceuticals and Biotechnology, Tianjin University, Tianjin, 300072, Peop. Rep. China

SO Chinese Chemical Letters (2003), 14(6), 581-584
CODEN: CCLEE7; ISSN: 1001-8417
PB Chinese Chemical Society
DT Journal
LA English
OS CASREACT 139:395672

L4 ANSWER 5 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I R=H
II R=-O-$CH_2$-$CH_2$-$NH_2$

AB Aryl amide oligomers with amphiphilic secondary structure were designed that attack bacteria by lysing their membranes. A variety of groups were appended to the lead compound to adjust its overall charge, hydrophobicity, and hydrophobic moment. An Arg-containing oligomer (I) was found to have good antimicrobial activity and low toxicity towards human erythrocytes. Of this series, II exhibited no toxicity.

AN 2004:209233 CAPLUS
DN 140:388528
TI Nontoxic membrane-active antimicrobial arylamide oligomers
AU Liu, Dahui; Choi, Sungwook; Chen, Bin; Doerksen, Robert J.; Clements, Dylan J.; Winkler, Jeffrey D.; Klein, Michael L.; De Grado, William F.
CS Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, 19104-6059, USA
SO Angewandte Chemie, International Edition (2004), 43(9), 1158-1162
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English

5/11/05

=>
Uploading C:\Program Files\Stnexp\Queries\10713566.str




chain nodes :
7 8 9 10 11 12 13 14 15 20 21
ring nodes :
1 2 3 4 5 6
chain bonds :
3-7 5-11 7-8 7-9 9-10 11-12 12-13 12-14 14-15 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 7-9 12-13 12-14 20-21
exact bonds :
3-7 5-11 9-10 11-12 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 20:CLASS 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

5/11/05




G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 18:19:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   8384 TO ITERATE

 11.9% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       162192 TO   173168
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 18:19:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 168727 TO ITERATE

100.0% PROCESSED  168727 ITERATIONS                            156 ANSWERS
SEARCH TIME: 00.00.03

L3          156 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             161.33     161.54

FILE 'CAPLUS' ENTERED AT 18:19:32 ON 11 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

5/11/05



FILE COVERS 1907 - 11 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 10 May 2005 (20050510/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4          69 L3

=> s l4 and neurolog?
          5016 NEUROLOG?
         20723 NEUROL
         20723 NEUROL
                 (NEUROL)
         22866 NEUROLOG?
                 (NEUROLOG? OR NEUROL)
L5           0 L4 AND NEUROLOG?

=> s l4 and neuro?
        478804 NEURO?
L6           0 L4 AND NEURO?

=> s l4 and cns
         32968 CNS
L7           0 L4 AND CNS

=> s l4 and nerv?
        386816 NERV?
L8           1 L4 AND NERV?

=> d abs fbib hitstr

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AB   Novel, non-peptidic small organic compds. having an affinity for cyclophilin
     (CyP)-type immunophilin proteins are reported.  These compds. are used for
     binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase
     activity.  Thus, 5-HOC6H3(CO2Me)2-1,3 was O-benzylated, hydrolized to the
     acid and treated with 3,4-Cl2C6H3NH2 to give 5-PhCH2OC6H3(CONHC6H3Cl2-
     3,4)2-1,3.  This compound gave complete protection against cell death in
     L-threo-3-hydroxyaspartic acid treated spinal cord slices.
AN   2002:575044  CAPLUS
DN   137:124993
TI   Trisubstituted carbocyclic cyclophilin binding compounds and their use
```

IN Wu, Yong-Qian; Belyakov, Sergei; Hamilton, Gregory; Limburg, David; Steiner, Joseph; Vaal, Mark; Wei, Ling; Wilkinson, Douglas
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2002059080 | A2 | 20020801 | WO 2002-US2538 | | 20020125 |
| | WO 2002059080 | A3 | 20021219 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | CA 2435829 | AA | 20020801 | CA 2002-2435829 | | 20020125 |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | | | | WO 2002-US2538 | W | 20020125 |
| | US 2002165275 | A1 | 20021107 | US 2002-57203 | | 20020125 |
| | US 6656971 | B2 | 20031202 | | | |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291365P | P | 20010517 |
| | EP 1360173 | A2 | 20031112 | EP 2002-706049 | | 20020125 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | | | | WO 2002-US2538 | W | 20020125 |
| | JP 2004532187 | T2 | 20041021 | JP 2002-559382 | | 20020125 |
| | | | | US 2001-263703P | P | 20010125 |
| | | | | US 2001-291965P | P | 20010521 |
| | | | | WO 2002-US2538 | W | 20020125 |
| | US 2004157919 | A1 | 20040812 | US 2003-713566 | | 20031114 |
| | | | | US 2002-57203 | A3 | 20020125 |

OS MARPAT 137:124993
IT **444343-09-3P 444343-19-5P 444343-20-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(trisubstituted carbocyclic cyclophilin binding compds.)
RN 444343-09-3 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-[(3,4-dichlorophenyl)methoxy]-N,N'-bis(3,4,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 444343-19-5 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-(2-naphthalenylmethoxy)-N,N'-bis[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 444343-20-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N,N'-bis(3,4-dichlorophenyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT **444342-99-8P 444343-14-0P 444343-15-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(trisubstituted carbocyclic cyclophilin binding compds.)

RN 444342-99-8 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-[(2'-cyano[1,1'-biphenyl]-4-yl)methoxy]-N,N'-bis(3-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 444343-14-0 CAPLUS
CN 1,3-Benzenedicarboxamide, N,N'-bis[4-chloro-3-(trifluoromethyl)phenyl]-5-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 444343-15-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N,N'-bis(3,4-dichlorophenyl)-5-[[3-[[(3,4-

dichlorophenyl)amino]carbonyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 18:18:42 ON 11 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 18:18:50 ON 11 MAY 2005
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          156 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 18:19:32 ON 11 MAY 2005
L4           69 S L3
L5            0 S L4 AND NEUROLOG?
L6            0 S L4 AND NEURO?
L7            0 S L4 AND CNS
L8            1 S L4 AND NERV?

=> s l4 and diseases
        209355 DISEASES
             1 DISEASESES
        209356 DISEASES
                  (DISEASES OR DISEASESES)
L9            0 L4 AND DISEASES

=> s l4 and disease
        763217 DISEASE
        209355 DISEASES
        860115 DISEASE
                  (DISEASE OR DISEASES)
L10           1 L4 AND DISEASE

=> s l10 not l8
L11           0 L10 NOT L8
```

5/11/05

```
=> s l4 and use
       1762774 USE
       3022742 USES
       4487998 USE
                 (USE OR USES)
L12          17 L4 AND USE

=> d abs bib fhitstr 1-17
```